MedTrace Logo

Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma

NCT00050674 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-12-27

No results posted yet for this study

Summary

Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.

Conditions

Interventions

DRUG

Filgrastim-SD/01

6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Schwartzberg, Lee, M.D.

    lead INDIV

Principal Investigators

  • Lee S Schwartzberg, MD, FACP · The West Clinic, PC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00050674 on ClinicalTrials.gov